AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 12,500 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric Loumeau sold 12,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $44.86, for a total value of $560,750.00. Following the completion of the sale, the insider owned 9,088 shares in the company, valued at approximately $407,687.68. This represents a 57.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

AnaptysBio Price Performance

NASDAQ:ANAB traded up $1.84 during trading hours on Thursday, reaching $47.53. The company had a trading volume of 416,584 shares, compared to its average volume of 693,419. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $48.44. The business’s 50 day moving average price is $38.13 and its 200-day moving average price is $28.60. The firm has a market cap of $1.32 billion, a PE ratio of -16.85 and a beta of 0.29.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The company had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. On average, analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has initiated a share buyback program on Friday, November 21st that allows the company to buyback $100.00 million in shares. This buyback authorization allows the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. HC Wainwright cut their price objective on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a report on Monday, November 24th. Stifel Nicolaus cut their price target on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Wall Street Zen raised AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Finally, Truist Financial raised their target price on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $55.40.

Institutional Investors Weigh In On AnaptysBio

A number of institutional investors have recently modified their holdings of the company. Larson Financial Group LLC lifted its stake in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares in the last quarter. Rhumbline Advisers increased its stake in AnaptysBio by 2.7% during the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after buying an additional 826 shares during the period. US Bancorp DE lifted its holdings in AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after buying an additional 979 shares in the last quarter. Bessemer Group Inc. boosted its position in AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 1,292 shares during the period. Finally, Corton Capital Inc. grew its stake in shares of AnaptysBio by 12.2% in the second quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 1,305 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.